NOM1

Summary

NOM1 (nucleolar protein with MIF4G domain 1, HGNC:13244) is a protein-coding gene on chromosome 7q36.3, encoding Nucleolar MIF4G domain-containing protein 1 (Q5C9Z4). Plays a role in targeting PPP1CA to the nucleolus. It is a selective cancer dependency (DepMap: 79.8% of cell lines).

Proteins that contain MIF4G (middle of eIF4G (MIM 600495)) and/or MA3 domains, such as NOM1, function in protein translation. These domains include binding sites for members of the EIF4A family of ATP-dependent DEAD box RNA helicases (see EIF4A1; MIM 602641) (Simmons et al., 2005 [PubMed 15715967]).

Source: NCBI Gene 64434 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 183 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 79.8% of screened cell lines
• MANE Select transcript: NM_138400

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13244
Approved symbol	NOM1
Name	nucleolar protein with MIF4G domain 1
Location	7q36.3
Locus type	gene with protein product
Status	Approved
Aliases	SGD1, PPP1R113
Ensembl gene	ENSG00000146909
Ensembl biotype	protein_coding
OMIM	611269
Entrez	64434

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 retained_intron, 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000275820, ENST00000460332, ENST00000469271, ENST00000472491, ENST00000475176, ENST00000485661, ENST00000486131, ENST00000489850, ENST00000851672, ENST00000851673

RefSeq mRNA: 2 — MANE Select: NM_138400 NM_001353366, NM_138400

CCDS: CCDS34787

Canonical transcript exons

ENST00000275820 — 11 exons

Exon	Start	End
ENSE00000977980	156963905	156964026
ENSE00000977981	156966270	156966402
ENSE00001019078	156969529	156973176
ENSE00001019082	156959851	156960174
ENSE00001019088	156954103	156954298
ENSE00001147611	156952474	156952598
ENSE00001197979	156949712	156950724
ENSE00003465084	156966961	156967092
ENSE00003526836	156963008	156963175
ENSE00003609529	156969087	156969196
ENSE00003686415	156962151	156962261

Expression profiles

Bgee: expression breadth ubiquitous, 251 present calls, max score 95.48.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.4228 / max 340.1525, expressed in 1793 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
82273	14.4228	1793

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelial cell of pancreas	CL:0000083	95.48	gold quality
visceral pleura	UBERON:0002401	89.46	gold quality
germinal epithelium of ovary	UBERON:0001304	88.40	gold quality
parietal pleura	UBERON:0002400	88.35	gold quality
gingival epithelium	UBERON:0001949	87.00	gold quality
body of pancreas	UBERON:0001150	86.42	gold quality
skin of abdomen	UBERON:0001416	86.27	gold quality
colonic epithelium	UBERON:0000397	85.92	gold quality
skin of leg	UBERON:0001511	85.76	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.73	gold quality
sural nerve	UBERON:0015488	85.41	gold quality
zone of skin	UBERON:0000014	85.40	gold quality
left ovary	UBERON:0002119	85.36	gold quality
stromal cell of endometrium	CL:0002255	84.90	gold quality
right ovary	UBERON:0002118	84.76	gold quality
gingiva	UBERON:0001828	84.75	gold quality
endothelial cell	CL:0000115	84.23	silver quality
body of uterus	UBERON:0009853	84.21	gold quality
ovary	UBERON:0000992	84.18	gold quality
pancreas	UBERON:0001264	84.08	gold quality
smooth muscle tissue	UBERON:0001135	83.99	gold quality
ectocervix	UBERON:0012249	83.98	gold quality
monocyte	CL:0000576	83.92	gold quality
Brodmann (1909) area 23	UBERON:0013554	83.83	gold quality
oviduct epithelium	UBERON:0004804	83.67	gold quality
gastrocnemius	UBERON:0001388	83.65	gold quality
vagina	UBERON:0000996	83.64	gold quality
upper lobe of left lung	UBERON:0008952	83.63	gold quality
omental fat pad	UBERON:0010414	83.63	gold quality
peritoneum	UBERON:0002358	83.59	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.65
E-HCAD-29	no	148.30

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

77 targeting NOM1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-132-3P	99.73	70.56	1424
HSA-MIR-212-3P	99.73	70.65	1424
HSA-MIR-1284	99.67	73.56	1353
HSA-MIR-586	99.65	70.40	2051
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-216A-5P	99.50	68.02	1288
HSA-MIR-217-5P	99.49	69.93	1419
HSA-MIR-20A-3P	99.44	69.10	1575
HSA-MIR-208A-5P	99.42	70.83	1913

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 79.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• Data demonstrate that NOM1 can target PP1 to the nucleolus and show NOM1 nucleolar localization sequence are required for this targeting activity and conclude that NOM1 is a PP1 nucleolar targeting subunit, the first identified in eukaryotic cells. (PMID:17965019)
• demonstrate direct physical interactions between yeast Sgd1p and Fal1p, and between their human orthologs (NOM1 and eIF4AIII) in vitro and in vivo, identifying human NOM1 as a missing eIF4G-like interacting partner of eIF4AIII (PMID:21576267)
• Results are consistent with a physiologically-relevant interplay between the nuclear IGF1 signaling pathway and nucleolar protein NOM1. (PMID:30639046)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	nom1	ENSDARG00000060027
mus_musculus	Nom1	ENSMUSG00000001569
rattus_norvegicus	Nom1	ENSRNOG00000048969
drosophila_melanogaster	CG9004	FBGN0035336
caenorhabditis_elegans	Y52B11A.10	WBGENE00013129

Paralogs (1): CWC22 (ENSG00000163510)

Protein

Protein identifiers

Nucleolar MIF4G domain-containing protein 1 — Q5C9Z4 (reviewed: Q5C9Z4)

Alternative names: SGD1 homolog

All UniProt accessions (1): Q5C9Z4

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in targeting PPP1CA to the nucleolus.

Subunit / interactions. May interact with EIF4A1, EIF4A2 and EIF4A3. Interacts with PPP1CA and PPP1CC.

Subcellular location. Nucleus. Nucleolus.

Tissue specificity. Expressed in heart and skeletal muscle.

Similarity. Belongs to the CWC22 family.

RefSeq proteins (2): NP_001340295, NP_612409* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003890	MIF4G-like_typ-3	Domain
IPR003891	Initiation_fac_eIF4g_MI	Domain
IPR016024	ARM-type_fold	Homologous_superfamily
IPR050781	CWC22_splicing_factor	Family

Pfam: PF02847, PF02854

UniProt features (29 total): compositionally biased region 8, sequence variant 6, modified residue 5, region of interest 4, domain 2, mutagenesis site 2, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5C9Z4-F1	70.73	0.30

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 57, 139, 317, 320, 321

Mutagenesis-validated functional residues (2):

Position	Phenotype
308	loss of interaction with ppp1ca and loss of ability to relocalize ppp1ca to the nucleolus; when associated with a-310.
310	loss of interaction with ppp1ca and loss of ability to relocalize ppp1ca to the nucleolus; when associated with a-308.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 55 (showing top): GOBP_RIBOSOME_BIOGENESIS, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_ANATOMICAL_STRUCTURE_MATURATION, GOBP_RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS, GOBP_MOLTING_CYCLE, GOBP_EPIDERMIS_DEVELOPMENT, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_SKIN_DEVELOPMENT, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, GOCC_NUCLEOLUS, GOBP_HAIR_FOLLICLE_MATURATION, CEBPZ_TARGET_GENES, CIITA_TARGET_GENES, FOXE1_TARGET_GENES, H1_6_TARGET_GENES

GO Biological Process (2): ribosomal small subunit biogenesis (GO:0042274), hair follicle maturation (GO:0048820)

GO Molecular Function (2): RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (2): nucleolus (GO:0005730), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ribonucleoprotein complex biogenesis	1
ribosome biogenesis	1
hair follicle development	1
hair cycle process	1
anatomical structure maturation	1
nucleic acid binding	1
binding	1
nuclear lumen	1
intracellular membraneless organelle	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1498 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NOM1	SMARCD2	Q92925	895
NOM1	EIF4A3	P38919	788
NOM1	RNF32	Q9H0A6	775
NOM1	LMBR1	Q8WVP7	728
NOM1	G6PD	P11413	712
NOM1	EIF4A2	Q14240	681
NOM1	H6PD	O95479	666
NOM1	RBM33	Q96EV2	643
NOM1	EIF4A1	P04765	635
NOM1	TDRD3	Q9H7E2	632
NOM1	EIF3G	O75821	626
NOM1	EIF4G1	Q04637	622
NOM1	UTP3	Q9NQZ2	613
NOM1	UBE3C	Q15386	575
NOM1	UTP25	Q68CQ4	563

IntAct

136 interactions, top by confidence:

A	B	Type	Score
EIF4A3	CASC3	psi-mi:“MI:0914”(association)	0.980
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
NOM1	EIF4A3	psi-mi:“MI:0915”(physical association)	0.690
NOM1	EIF4A3	psi-mi:“MI:0407”(direct interaction)	0.690
MAPK7	PFDN6	psi-mi:“MI:0914”(association)	0.640
NEUROG3	GXYLT2	psi-mi:“MI:0914”(association)	0.640
LIN28A	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
RPS14	CCZ1B	psi-mi:“MI:0914”(association)	0.640
NPM1	MPHOSPH10	psi-mi:“MI:0914”(association)	0.610
NOM1	NGDN	psi-mi:“MI:0915”(physical association)	0.560
SRPK2	NOM1	psi-mi:“MI:0915”(physical association)	0.560
NOM1	RPLP0	psi-mi:“MI:0914”(association)	0.530
FBL	ZNF316	psi-mi:“MI:0914”(association)	0.530
GTF3C2	C1QBP	psi-mi:“MI:0914”(association)	0.530
MAGEB2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
RPS2	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
KRR1	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
CXCR4	FANCA	psi-mi:“MI:0914”(association)	0.530
RRP8	MAGEB2	psi-mi:“MI:0914”(association)	0.530
LIN28B	ELAVL2	psi-mi:“MI:0914”(association)	0.530
LRRTM4	AP3B1	psi-mi:“MI:0914”(association)	0.530
RPL13	RRP8	psi-mi:“MI:0914”(association)	0.530
NOM1	PPP1CA	psi-mi:“MI:0915”(physical association)	0.370
Calu	CACNA2D1	psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
M	NPEPPSL1	psi-mi:“MI:0914”(association)	0.350
PB2	ESYT2	psi-mi:“MI:0914”(association)	0.350
NS1	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (162): NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS), NOM1 (Affinity Capture-MS)

ESM2 similar proteins: A1Z623, A2SXS5, A8YXY3, F1LQY6, O02718, O19011, O60613, P01137, P04202, P07200, P09533, P11456, P18341, P50747, P54831, Q08BI9, Q0P5I0, Q1LZ96, Q2KIJ6, Q2TBX5, Q38HS2, Q3UHE1, Q3UX43, Q58CS8, Q5C9Z4, Q5R812, Q5RB75, Q6IEE6, Q6PCX7, Q6X4M2, Q802F3, Q802G7, Q8BJQ9, Q8IVD9, Q8NC56, Q8R1N4, Q8R1T1, Q8TDX6, Q8VHC3, Q8WUX9

Diamond homologs: O13971, Q06132, Q3UFM5, Q5C9Z4, P0DP80, P0DP81, Q9W020, Q4PCY0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 152 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Eukaryotic Translation Elongation	8	21.6×	9e-08
Eukaryotic Translation Initiation	7	21.0×	8e-07
Cap-dependent Translation Initiation	7	21.0×	8e-07
SARS-CoV-1 modulates host translation machinery	7	21.0×	8e-07
Peptide chain elongation	15	18.5×	3e-13
Viral mRNA Translation	15	18.5×	3e-13
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S	7	18.5×	2e-06
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	15	18.3×	3e-13

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of mRNA splicing, via spliceosome	5	28.8×	9e-05
ribosomal large subunit biogenesis	7	23.3×	3e-06
cytoplasmic translation	15	20.9×	3e-13
ribosomal small subunit biogenesis	12	20.6×	2e-10
translation	14	10.8×	1e-08
rRNA processing	10	10.7×	5e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

183 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	154
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1824 predictions. Top by Δscore:

Variant	Effect	Δscore
7:156950719:GA:G	donor_gain	1.0000
7:156950720:A:G	donor_gain	1.0000
7:156952468:A:AG	acceptor_gain	1.0000
7:156952470:GCAGA:G	acceptor_gain	1.0000
7:156952473:GA:G	acceptor_gain	1.0000
7:156952552:G:GT	donor_gain	1.0000
7:156952595:ACAG:A	donor_loss	1.0000
7:156952596:CAG:C	donor_loss	1.0000
7:156952598:GG:G	donor_loss	1.0000
7:156952599:G:GC	donor_loss	1.0000
7:156954089:A:AG	acceptor_gain	1.0000
7:156954090:C:G	acceptor_gain	1.0000
7:156954091:A:AG	acceptor_gain	1.0000
7:156954092:A:G	acceptor_gain	1.0000
7:156954093:T:G	acceptor_gain	1.0000
7:156954098:T:TA	acceptor_gain	1.0000
7:156954098:TGCA:T	acceptor_loss	1.0000
7:156954100:CAGGT:C	acceptor_loss	1.0000
7:156954101:A:AG	acceptor_gain	1.0000
7:156954101:A:T	acceptor_loss	1.0000
7:156954101:AG:A	acceptor_gain	1.0000
7:156954101:AGGTT:A	acceptor_gain	1.0000
7:156954102:G:GT	acceptor_gain	1.0000
7:156954102:GG:G	acceptor_gain	1.0000
7:156954102:GGT:G	acceptor_gain	1.0000
7:156954102:GGTT:G	acceptor_gain	1.0000
7:156954102:GGTTG:G	acceptor_gain	1.0000
7:156954297:AG:A	donor_loss	1.0000
7:156954298:GGT:G	donor_loss	1.0000
7:156954299:G:A	donor_loss	1.0000

AlphaMissense

5682 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:156963092:T:A	W610R	0.998
7:156963092:T:C	W610R	0.998
7:156960083:G:C	R514T	0.997
7:156960084:G:C	R514S	0.997
7:156960084:G:T	R514S	0.997
7:156963930:C:A	A646D	0.997
7:156962157:T:C	F547L	0.995
7:156962159:T:A	F547L	0.995
7:156962159:T:G	F547L	0.995
7:156963094:G:C	W610C	0.995
7:156963094:G:T	W610C	0.995
7:156950294:T:C	I186T	0.994
7:156962186:G:C	K556N	0.994
7:156962186:G:T	K556N	0.994
7:156963089:T:A	W609R	0.994
7:156963089:T:C	W609R	0.994
7:156963945:T:C	M651T	0.994
7:156960083:G:T	R514M	0.992
7:156962182:T:C	L555P	0.991
7:156963960:G:C	R656P	0.990
7:156963971:T:C	F660L	0.990
7:156963973:C:A	F660L	0.990
7:156963973:C:G	F660L	0.990
7:156966311:T:A	V692D	0.990
7:156954103:G:C	R371S	0.989
7:156954103:G:T	R371S	0.989
7:156960071:G:A	G510D	0.989
7:156963091:G:C	W609C	0.989
7:156963091:G:T	W609C	0.989
7:156964020:T:C	L676P	0.989

dbSNP variants (sampled 300 via entrez): RS1000043819 (7:156952998 G>A), RS1000078474 (7:156968695 A>T), RS1000267647 (7:156955041 G>A), RS1000530213 (7:156954574 G>A), RS1000619224 (7:156948255 C>T), RS1000681431 (7:156949572 T>A), RS1000701473 (7:156955238 C>A), RS1000851879 (7:156968297 C>T), RS1001090993 (7:156959714 G>T), RS1001103837 (7:156958784 C>T), RS1001147260 (7:156956859 A>G), RS1001157029 (7:156956560 A>G), RS1001291418 (7:156950808 C>G), RS1001366500 (7:156963613 G>A), RS1001407053 (7:156951103 C>T)

Disease associations

OMIM: gene MIM:611269 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): strabismus (MONDO:0003432), congenital pulmonary veins anomaly (MONDO:0020295)

Orphanet (1): Congenital pulmonary veins anomaly (Orphanet:98729)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003050_23	Schizophrenia	4.000000e-06
GCST009675_6	Urinary magnesium excretion	9.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004845	magnesium measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D013285	Strabismus	C10.292.562.887; C11.590.810

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067109 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.49	Kd	3.217	nM	CHEMBL3752910
8.49	ED50	3.217	nM	CHEMBL3752910

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149898: Binding affinity to human NOM1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0032	uM

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases expression, increases expression, affects cotreatment	3
bisphenol A	decreases methylation, decreases expression	2
Valproic Acid	affects expression, increases expression	2
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
coumarin	decreases phosphorylation	1
4-phenylbutyric acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
Resveratrol	increases expression, affects cotreatment	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Azacitidine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Coumestrol	increases expression, affects cotreatment	1
Bucladesine	affects cotreatment, decreases expression	1
Fluorouracil	decreases expression	1
Formaldehyde	decreases expression	1
Plant Extracts	increases expression, affects cotreatment	1
Ribonucleotides	affects binding	1
Smoke	decreases expression	1
Urethane	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Aflatoxin B1	increases expression	1
Medroxyprogesterone Acetate	affects cotreatment, decreases expression	1
Cadmium Chloride	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652940	Binding	Binding affinity to human NOM1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

102 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00461656	PHASE4	COMPLETED	Povidone-iodine Antisepsis for Strabismus Surgery
NCT01901588	PHASE4	COMPLETED	Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery
NCT02379546	PHASE4	COMPLETED	The Effect of Anaesthesia Depth on Oculo-cardiac Reflex
NCT03349515	PHASE4	COMPLETED	The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia.
NCT04549844	PHASE4	UNKNOWN	Peribulbar Block for Prevention of Oculocardiac Reflex
NCT06035757	PHASE4	RECRUITING	The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
NCT06560268	PHASE4	NOT_YET_RECRUITING	Low Flow Anesthesia in Children Undergoing Strabismus Surgery
NCT00000128	PHASE3	UNKNOWN	A Trial of Bifocals in Myopic Children With Esophoria
NCT00001864	PHASE3	COMPLETED	Amblyopia (Lazy Eye) Treatment Study
NCT00038753	PHASE3	UNKNOWN	Vision In Preschoolers Study (VIP Study)
NCT01584843	PHASE3	COMPLETED	Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus
NCT04060771	PHASE3	UNKNOWN	Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery
NCT06863675	PHASE3	NOT_YET_RECRUITING	Highly Aspherical Lenslet (HAL) and Binocular Vision (BV) Disorders [HALT X(T) Study]
NCT00478907	PHASE2	COMPLETED	Prevention of Complications of Eye Surgery
NCT06689943	PHASE2	NOT_YET_RECRUITING	Pain After Strabismus Surgery
NCT00917982	PHASE1	UNKNOWN	The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7 Years Old Strabismic Patients
NCT02246556	PHASE1	TERMINATED	Dichoptic Virtual Reality Therapy for Amblyopia in Adults
NCT01616108	PHASE2/PHASE3	UNKNOWN	Bupivacaine Injection of Eye Muscles to Treat Strabismus
NCT00001143	Not specified	COMPLETED	Development of the Eye Motor System During the First 7 Months of Life in Infants With and Without a Family History of Cross-Eye
NCT00001861	Not specified	COMPLETED	Screening for Studies on Nystagmus and Strabismus
NCT00304577	Not specified	COMPLETED	Bilateral Recession or Unilateral Recession-Resection as Surgery for Infantile Esotropia
NCT00338559	Not specified	COMPLETED	Does LMA Instead of ET Tube Affect Incidence of Postoperative Vomiting in Children Undergoing Strabismus Correction?
NCT00535938	Not specified	COMPLETED	MDs on Botox Utility (MOBILITY)
NCT00559234	Not specified	COMPLETED	Potential Research Participants for Future Studies of Inherited Eye Diseases
NCT01109459	Not specified	COMPLETED	Multimodal Physician Intervention to Detect Amblyopia
NCT01430247	Not specified	COMPLETED	Vision Screening for the Detection of Amblyopia
NCT01512355	Not specified	COMPLETED	The Effect of Dexmedetomidine on Decreasing Emergence Agitation and Delirium in Pediatric Patients Undergoing Strabismus Surgery
NCT01608828	Not specified	COMPLETED	Assessing the Functional and Psychosocial Impact of Strabismus in Asian Children Using the AS-20 and IXTQ Questionnaires
NCT01706991	Not specified	COMPLETED	Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner
NCT01726842	Not specified	COMPLETED	Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner
NCT01791946	Not specified	COMPLETED	Binocular Treatment of Amblyopia Before and After Strabismus Surgery
NCT01812044	Not specified	COMPLETED	Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery
NCT01832883	Not specified	COMPLETED	Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner
NCT02113709	Not specified	UNKNOWN	Determining the Efficacy of Full-time Occlusion Therapy in Severe Amblyopia at Different Ages
NCT02152787	Not specified	UNKNOWN	Comparison of Propofol 1mg/kg and Propofol 0.5mg/kg for Prevention of Emergence Agitation in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia
NCT02228070	Not specified	COMPLETED	Strabismus Measurements Using Automated 3D Video Oculography
NCT02236351	Not specified	UNKNOWN	New Pediatric Patching Method to Improve Compliance
NCT02360969	Not specified	COMPLETED	Effect of Neuromuscular Blockade on the Oculomotor by Not Squinting Child
NCT02454920	Not specified	COMPLETED	Measurement of Insertion of Extraocular Muscles Using Anterior Segment Optical Coherence Tomography
NCT02455401	Not specified	COMPLETED	Effect of Remifentanil on Postoperative Vomiting in Pediatric Strabismus Surgery